European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of the combination of avelumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This recommendation is based on findings from the phase III JAVELIN Renal 101 study involving 886 patients, which demonstrated significant improvements in median […]

read more

Steve Pointon launches his 40 for 40 fundraising challenge

Please get behind Steve to support him during his 40 days of fitness before he turns 40! All donations will help support KCSN and The Christie Hospital in Manchester and are very much appreciated! Please donate via JustGiving or visit the KCSN website here Read about Steve’s challenge in Stoke-on-Trent Live here

read more

Tivozanib in heavily pre-treated advanced kidney cancer patients

Further data from the TIVO-3 clinical trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma (RCC), which is unresponsive to treatment (refractory), has shown that at 32.5 months, 20 patients on tivozanib remain progression free, versus 2 patients on sorafenib. This is despite there being no positive effect on overall survival (median […]

read more

PD-L1 expression and clinical outcomes with targeted therapy

A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy. Positive expression of the PD-L1 receptor on RCC tumour cells was associated […]

read more

Immune checkpoint inhibitors are more effective in PD-L1 positive patients

Immune checkpoint inhibitors, such as nivolumab, ipilimumab or pembrolizumab are often used alone or in combination with other drugs for the treatment of metastatic renal cell carcinoma (RCC). Unfortunately, researchers are yet to identify a reliable biomarker to predict a patient’s response to immune checkpoint inhibitors. PD-L1 is a potential biomarker for the effectiveness of […]

read more
Showing 1 to 6 of 662 results
  TOP